Q-omics provides the consensus-scored PTK2B profile across patient tissues and cancer cell-line models. PTK2B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PTK2B is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, PTK2B protein abundance shows 24,961 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, HNSC, and LSCC as cancer lineages where PTK2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PTK2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PTK2B survival associations across molecular data types. PTK2B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PTK2B RNA expression–survival associations across cancer types. High PTK2B expression shows unfavorable associations in LGG, but favorable associations in SKCM, THCA, CESC, BLCA and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PTK2B RNA expression.
This table summarizes PTK2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PTK2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PTK2B shows lower tumor expression in LUAD, COAD, KIRC and UCEC and higher tumor expression in HNSC and THCA. The HNSC box plot shows higher PTK2B RNA expression in tumor versus normal tissue (log2 FC = +0.814, t-test p < 0.001).
This table shows molecular features associated with PTK2B in patient tissues and cancer cell lines. In patient samples, PTK2B shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PTK2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
